STAT Plus: GSK took a leap of faith on PARP inhibitors in cancer. It may pay off
AKIRA SUEMORI/AP
The company has argued that that there are diseases beyond breast and ovarian cancer in which the drug Zejula would work in a larger group of patients.
Clinical and Molecular Allergy
Hace 20 horas
No hay comentarios:
Publicar un comentario